Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Longchuan Bai

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The Journal of Allergy and Clinical Immunology|May 22, 2024
IL-4-STAT6 axis amplifies histamine-induced vascular endothelial dysfunction and hypovolemic shockJames Krempski, Amnah Yamani, Lakshmi Narasimha Rao Thota, et al.
Journal of Medicinal Chemistry|March 25, 2017
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor RegressionBing Zhou, Jiantao Hu, Fuming Xu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry|May 3, 2017
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain InhibitorYujun Zhao, Longchuan Bai, Liu Liu, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Journal of Medicinal Chemistry|August 22, 2025
Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue DegradersXuqing Zhang, Harshil Dhruv, Qiaolin Deng, et al.
Nature Chemical Biology|February 2, 2023
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivoAtsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Medicinal Chemistry|November 7, 2024
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor RegressionRenqi Xu, Haibin Zhou, Longchuan Bai, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Allergy and Clinical Immunology|May 22, 2024
IL-4-STAT6 axis amplifies histamine-induced vascular endothelial dysfunction and hypovolemic shockJames Krempski, Amnah Yamani, Lakshmi Narasimha Rao Thota, et al.
Journal of Medicinal Chemistry|March 25, 2017
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor RegressionBing Zhou, Jiantao Hu, Fuming Xu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry|May 3, 2017
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain InhibitorYujun Zhao, Longchuan Bai, Liu Liu, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Journal of Medicinal Chemistry|August 22, 2025
Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue DegradersXuqing Zhang, Harshil Dhruv, Qiaolin Deng, et al.
Nature Chemical Biology|February 2, 2023
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivoAtsunori Kaneshige, Longchuan Bai, Mi Wang, et al.
Journal of Medicinal Chemistry|November 7, 2024
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor RegressionRenqi Xu, Haibin Zhou, Longchuan Bai, et al.
Pageof 7